Fort Worth, TX – March 20th, 2024 – EnlivenHealth, a division of Omnicell, Inc. (Nasdaq: OMCL), today announced the official launch of their patented¹ Digital Medication Information Delivery (DMID) solution, a patient engagement solution that is designed to electronically send FDA-required medication information — including drug monographs, FDA Medication Guides, CDC Vaccine Information Statements and other health and medication literacy information — to pharmacy patients, which is designed to improve patient access and education while promoting environmental and sustainability efforts by reducing paper and toner cartridge waste.
Recent research shows the use of medicines in the U.S. — based on defined daily doses — has grown 7.2% from 2018 to 2022 to nearly 243 billion days of therapy in both retail and non-retail settings in 2022². As medicine usage increases, DMID aims to provide pharmacists with a more efficient method to supply information to patients and to give patients an easier way to keep and access prescription printouts. When patients discard the printed handouts pharmacists provide with their prescriptions, patients can lose access to important information, pharmacies could face heavier workloads due to increased questions, and patients may struggle with adherence or face higher safety risks. With growing use of medicines, pharmacies may also face a paper consumption and waste crisis that could contribute to growing environmental challenges.
EnlivenHealth’s DMID is designed to not only reduce the cost and environmental impact of printed paper, but is also developed with the clinical intent of improving patient literacy and it ultimately seeks to improve the outcomes of any medication therapy. EnlivenHealth believes pharmacies can accomplish this by optimizing when medication information is shared, the completeness of the content shared, and how it is shared. For example, with DMID, patients are able to receive medication information conveniently via QR code, SMS text, mobile app push, or email, which is intended to seamlessly integrate with existing pharmacy workflows with the ability to be timed to when a prescription is ready for pick up or at the point of sale, when the prescription has been dispensed to the patient. This optimized workflow process is designed to improve patient access, education, outcomes, and pharmacy efficiency.
A major retail pharmacy chain launched EnlivenHealth’s DMID solution to a cohort of stores in Q3 of 2023, deploying to over 1900 locations by Q4 of 2023. Its strategic initiative focuses on reducing their carbon footprint by digitizing the medication information and enhancing patient outcomes through improved health literacy.
“We believe EnlivenHealth’s DMID solution represents a significant step forward in modernizing patient care and pharmacy operations,” said Martha Thorne, Senior Vice President and General Manager of EnlivenHealth. “By providing patients with easy access to digital medication information, we seek to empower them to take control of their health, while reducing environmental impact. We are excited to partner with pharmacies to transform the patient experience.”
For more information about EnlivenHealth and its DMID solution, visit https://enlivenhealth.co/.
Sources:
- United States Patent, Patent No.: US 11,676197 B2 https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11676197
- IQVIA Institute: The Use Of Medicines In The U.S. 2023 Usage And Spending Trends And Outlook To 2027, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2023
About EnlivenHealth®
EnlivenHealth, a division of Omnicell, Inc. enables pharmacies with connected patient engagement, clinical, and financial workflows designed to result in an elevated patient-pharmacy experience, exceptional patient care, and enhanced financial performance. We advocate for a world where pharmacy teams stand at the forefront of healthcare, empowering them to practice at the top of their license, and aiding them with their commitment to patient care, collaboration, and continuous learning.
To learn more, visit EnlivenHealth.co.
ENLIVENHEALTH is a registered trademark of Omnicell, Inc. or one of its subsidiaries.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
Forward-Looking Statements
Certain statements contained in this press release relate to the expected benefits and objectives of EnlivenHealth’s products and services, including EnlivenHealth’s Digital Medication Information Delivery solution (and any implied financial impact in connection with the foregoing). These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties many of which are beyond our control. These risks and uncertainties include, among other things, (i) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (ii) risks related to Omnicell’s investments in new business strategies or initiatives, (iii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (iv) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (v) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (vi) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (vii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (viii) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (ix) Omnicell’s ability to protect its intellectual property, (x) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, and (xi) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
Contact:
Rick Cedrone
Sr Director, Marketing at EnlivenHealth
rick.cedrone@omnicell.com